GOLD - New High $3448

You don't hear a lot about gold from the general press, but gold closed at an all-time, new high last week at $3448 / ounce. The usual reasons we posted here Gold - New High are in play and haven't changed. Chart below of gold, thank you for reading. 

NUVB: Nuvation Bio ($2.75) - Update #3

An update on Nuvaton Bio's progress the past few months, as the company and stock have been performing well since receiving FDA approval of Taletrectinib, a drug for ROS1-positive non small cell lung cancer (NSCLC). Another drug in their pipeline NUV-1511 is in clinical studies for five indications. 

 Financial Statistics: 

• $608 million cash
• Debt - minimal
• 341 million diluted shares outstanding
• 938 million market cap

Intellectual Property:

• Taletrectinib - Expected to expire from 2033 to 2042
• Safusidenib - Expected to expire from 2035 to 2041
• NUV-1511 - Expected to expire 2039 to 2043

Nuvation Bio's pipeline includes NUV-1511 a drug known as a DCC (drug-drug conjugate), which is in a phase 1/2 being tested for patients with advanced solid tumors in five separate indications here NUV-1511. This large study will include 466 patients to conclude in early 2027. The company expects more details forthcoming. Weekly chart below of Nuvation, thank you for reading. 

Axsome 2nd Quarter Financial Results ($103.59)

Axsome Therapeutics is getting closer to becoming a profitable company, on a cash and earnings per share basis.  An impressive 2nd quarter, with highlights below. 

• On target to file a supplemental NDA for Alzheimer's Agitation 3rd quarter
• 150 million in second quarter revenue
• 303 million in cash

Chart below of Axsome Therapeutics, with corrections that the stock has endured the last few years. The average correction falls in the range of around 30%. Thank you for reading.